跳至主要内容
临床试验/NCT04695431
NCT04695431已完成不适用

An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared With Best Available Therapy for Patients With Advanced Systemic Mastocytosis

Blueprint Medicines Corporation6 个研究点 分布在 5 个国家目标入组 317 人开始时间: 2020年12月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
317
试验地点
6
主要终点
Comparative evaluation of overall survival (OS) between patients receiving best available therapy versus avapritinib in BU-285-2101 and BLU-285-2202

研究概览

简要总结

BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Comparative evaluation of overall survival (OS) between patients receiving best available therapy versus avapritinib in BU-285-2101 and BLU-285-2202

时间窗: up to 12 years

Overall Survival defined as time from initiation of systemic treatment to death from any cause

次要结局

  • Comparative evaluation between patients receiving best available therapy versus avapritinib of duration of treatment (DOT)(Up to 12 years)
  • Comparative evaluation between patients receiving best available therapy versus avapritinib and time to next treatment line (TtNTL)(Up to 12 years)
  • Comparative evaluation of change in serum tryptase concentration in patients receiving best available therapy versus avapritinib(Up to 12 years)
  • To characterize the safety profile and conduct comparative evaluation of safety between patients receiving best available therapy vs. avapritinib(Up to 12 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验